Process Monitoring
with At-Line Biosensors

The ImmunoQube™ integrates newly discovered nanobodies into an automated instrument for multiplexed, at-line protein quantification.
QBI employs sdAbs towards process monitoring and at-line sensing, spanning targets from small molecules, proteins, and whole cells.

Through a novel agglutination method based on E. coli-displayed sdAbs, we sense analytes quantitatively and in real time. These sensors have been deployed in a variety of field and laboratory settings, showcasing the stability and robustness of single-domain antibodies for biosensing applications.

Lorem ipsum dolor sit amet, ex etiam civibus pro, soluta labitur scriptorem ex ius, nonumes menandri quo ne. Sonet affert eam id, erat possit convenire ex ius, ad cum feugiat accusata expetendis. Tale nonumes ad duo, ne elit docendi vix, at percipit intellegam honestatis ius.

ImmunoQube™ is a novel at-line biosensor platform

Customizable, continuous, quantitative, and multiplexed real time control, quantify targets at very low concentrations, autonomously and at line.

Quantify targets at very low concentrations

Optimal applications of QBI’s at-line biosensors:

  • Continuous, automated sensing

  • ELISA-type detection in real time

  • CMC, process science, quality control, assay development

  • Reduce labor and increase sampling frequency

  • Increase output of pharma manufacturing

  • Perform in-line quality control

  • ELISA-type detection in real time

  • Sensing monoclonal antibodies and other proteins for pharmaceutical manufacturing

Leverage a proprietary synthetic, high-diversity phage-display library of single-domain binders.

QBI’s At-line Biosensor Platform
Utilizes high-throughput microfluidics for nanobody screening.

Enables customizable, repeated measurements of desired targets, and continuous, automated sensing.

Increases output, reduces labor, and allows for real time ELISA-type detection.